logo
episode-header-image
Oct 2024
23m 58s

Hot shot: the wider promise of weight-lo...

The Economist
About this episode

First they treated diabetes. Then obesity. Now GLP-1 drugs are being tested on a range of other diseases too. Though the US economy is roaring, many Americans are glum about its prospects. How could that affect the election (9:02)? And our podcast on why Chinese migrants are making perilous journeys through the jungle to reach America (16:55).


Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+


For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. 




Hosted on Acast. See acast.com/privacy for more information.

Up next
Yesterday
Silver-year strongman: 25 years of Narendra Modi
We examine the record of the man at the helm of India’s government. As protests pose a fresh threat, where will he take the country next? From New Hampshire to Virginia, our American-midterms series takes you to the races you might be missing. And the life of Winston Churchill’s ... Show More
27m 50s
Oct 29
Effective non-altruism: Elon Musk’s foundation
The world’s richest person does not say much nice about philanthropy, and his foundation does not say much about itself. Our correspondent digs deeper. The next stop for our midterm-elections series is Kansas, where a Republican-seeming Democrat has an unlikely shot at the Senate ... Show More
23m 2s
Oct 28
Bye bye Bibi? Israel’s election results
Binyamin Netanyahu has underperformed but so has his main opponent, Gadi Eisenkot. Who will form a government? We decipher what the messy results mean for Israel. Our American-midterms series heads south to Georgia. And how film critics and audiences have agreed to disagree.Guest ... Show More
21m 19s
Recommended Episodes
Dec 2024
068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond
Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ... Show More
11m 16s
Dec 2024
A checkup on weight-loss drugs
What started as a story about Hollywood waistlines has become a global phenomenon. Weight loss drugs are becoming more and more mainstream a few years after making their dramatic debut. On this weekend episode of Reuters World News, our health reporters weigh in on the impact of ... Show More
20m 17s
Feb 2024
The obesity drug craze is entering its next phase
Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More
22m 46s
Nov 2025
The end of dieting
The Trump administration is making GLP-1s more affordable. This class of drugs seems to have forever changed the game on diet and exercise for Americans. This episode was produced by Miles Bryan, edited by Jolie Myers, fact-checked by Laura Bullard, engineered by Patrick Boyd and ... Show More
25m 50s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ... Show More
36m 59s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
<p>More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ... Show More
36m 59s